查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401901

2030 年神经诊断市场预测：按产品、最终用户按症状和地区进行全球分析

Neurodiagnostics Market Forecasts to 2030 - Global Analysis By Product, By Condition End User, By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球神经诊断市场规模为 86 亿美元，预计到 2030 年将达到 162 亿美元，预测期内复合年增长率为 9.3%。

神经诊断学是指专注于评估和监测神经系统结构和功能的医学诊断领域。为了诊断和评估癫痫、中风和神经退化性疾病疾病等神经系统疾病，我们使用各种非侵入性方法，如脑电图 (EEG)、磁振造影(MRI)、电脑断层扫描(CT) 和神经传导研究。 - 使用侵入性方法。神经诊断在理解和管理影响大脑和神经系统的疾病方面发挥着重要作用。

帕金森氏症基金会公布的资料显示，2021年，美国估计有93万人患有帕金森氏症，预计2030年将增加至120万人。

神经系统疾病增加

随着阿兹海默症、癫痫和多发性硬化症等疾病的全球负担日益加重，人们对准确诊断工具的需求不断增长，以促进早期检测和有效管理。神经诊断技术，包括先进的成像方式和电生理测试，在深入了解神经系统的结构和功能方面发挥着至关重要的作用。此外，人们对早期诊断重要性的认识不断提高，加上神经诊断技术的不断进步，正在推动市场向前发展。

神经诊断设备高成本

神经诊断设备的高成本是神经诊断市场的主要抑制因素。神经诊断中使用的先进技术，例如先进的影像和监测设备，价格昂贵。这种高成本是神经诊断工具普及的障碍，特别是对于小型和预算有限的设施。此外，这种经济负担可能会限制尖端神经诊断技术的获取，阻碍全面神经学评估的可能性，并阻碍神经诊断市场的整体成长。

神经诊断设备的技术进步

持续的技术创新，例如高解析度成像技术、用于远端监控的可穿戴设备以及用于资料分析的人工智慧应用的开发，提高了诊断准确性和患者照护。这些进步为医疗专业人员提供了对神经系统疾病更全面的了解。随着神经诊断技术的发展，提高诊断准确性、简化工作流程和改善患者治疗效果的潜力正在增加，从而推动了市场的进一步采用和扩张。

医疗专业人员缺乏认识

儘管神经诊断技术不断进步，但医疗保健专业人员在理解和认识方面可能存在巨大差距。这种知识的缺乏可能会导致创新神经诊断程序和工具的延迟采用或利用不足。此外，认识不足会妨碍神经系统疾病的及时诊断和治疗并影响患者的治疗结果。

COVID-19 的影响：

COVID-19 的爆发对神经诊断市场产生了重大影响。封锁、选择性手术的限制以及医疗资源的重新分配减少了常规神经诊断测试。此外，患者因担心感染疾病而不愿去医疗机构就诊，进一步阻碍了市场。然而，大流行加速了远端医疗和远端监控解决方案的采用，为神经诊断市场提供了机会。

诊断和成像系统产业预计将在预测期内成为最大的产业。

由于技术进步以及对精确和非侵入性诊断工具的需求不断增长，诊断和成像系统领域预计将在预测期内主导神经诊断市场。磁振造影(MRI)、电脑断层扫描 (CT) 和正子断层扫描 (PET) 等先进影像技术有助于准确的神经系统诊断。此外，神经系统疾病发生率的增加凸显了诊断和影像系统在市场上的重要性。

头痛疾病领域预计在预测期内复合年增长率最高

预计在预测期内，头痛疾病领域的神经诊断市场将显着成长。头痛（包括偏头痛）盛行率的增加、意识的提高以及针对头痛疾病的诊断技术的进步等因素促成了这种扩张。随着医疗保健提供者优先考虑为头痛患者提供准确的诊断和个体化治疗计划，针对该细分市场量身定制的神经诊断工具和程序的需求预计将增加，从而推动整体市场成长。

占有率最大的地区：

预计在预测期内，北美将保持其在神经诊断领域的市场主导地位。该地区受益于完善的医疗基础设施、先进的技术以及大量的研发投资。此外，神经系统疾病的日益普及、人口高龄化和意识的提高也促进了对神经诊断服务的持续需求。产业领导者的存在和有利的法规环境进一步加强了北美在神经诊断市场的地位。

复合年增长率最高的地区：

预计亚太地区神经诊断市场将显着成长。人口快速成长、医疗意识提高以及神经系统疾病增加等因素正在推动对先进诊断技术的需求。该地区各国政府正在投资卫生基础设施、促进研究和开发并促进技术采用。由于对医疗保健品质和可及性的日益重视以及高龄化，亚太地区神经诊断市场预计将显着扩大。

免费客製化服务

如果您订阅此报告，我们将为您提供以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球神经诊断市场：副产品

  • 介绍
  • 诊断/影像系统
    • 血管造影术系统
    • 电脑断层扫描 (CT) 扫描仪
    • 脑电图（EEG）系统
    • 肌电图 (EMG) 设备
    • 磁振造影（MRI）系统
    • 脑磁图 (MEG) 设备
    • 正子断层扫描 (PET) 扫描仪
    • 超音波影像成像系统
    • 其他诊断/影像系统
  • 临床诊断设备
    • 新一代定序设备
    • 聚合酶连锁反应（PCR）装置
    • Sanger序器
    • 其他临床诊断设备
  • 试剂及消耗品
    • 抗体
    • 缓衝液
    • 酵素、蛋白质、胜肽
    • 培养基/血清
    • 探测
    • 溶剂
    • 其他试剂及消耗品
  • 其他产品

第六章全球神经诊断市场：依情况

  • 介绍
  • 神经退化性疾病
  • 癫痫
  • 头痛症
  • 睡眠失调
  • 其他条件

第七章全球神经诊断市场：依最终使用者分类

  • 介绍
  • 医院
  • 门诊治疗中心
  • 诊断实验室和影像中心
  • 神经中枢
  • 研究机构和学术机构
  • 其他最终用户

第八章全球神经诊断市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • GE Healthcare
  • Advanced Brain Monitoring, Inc
  • Bio-Rad Laboratories
  • Canon, Inc.
  • F. Hoffmann-La Roche AG
  • Fujifilm Corporation
  • GE Healthcare
  • Hitachi Ltd.
  • Hoffman-La Roche AG
  • Koninklijke Philips NV
  • Lifelines Neuro Company LLC
  • Mitsar Co. Ltd.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • QIAGEN NV
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
Product Code: SMRC24421

According to Stratistics MRC, the Global Neurodiagnostics Market is accounted for $8.6 billion in 2023 and is expected to reach $16.2 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Neurodiagnostics refers to the field of medical diagnostics that focuses on the assessment and monitoring of the nervous system's structure and function. It involves various non-invasive and invasive techniques, such as electroencephalography (EEG), magnetic resonance imaging (MRI), computed tomography (CT), and nerve conduction studies, to diagnose and evaluate neurological disorders, including epilepsy, stroke, and neurodegenerative diseases. Neurodiagnostics plays a crucial role in understanding and managing conditions affecting the brain and nervous system.

According to the data published by the Parkinson's Foundation, in 2021, an estimated 9,30,000 people were living with Parkinson's disease in the United States 2020, and this number is predicted to increase to 1,2 million by 2030.

Market Dynamics:

Driver:

Increasing incidence of neurological disorders

With a rising global burden of conditions such as Alzheimer's disease, epilepsy, and multiple sclerosis, there's an increased demand for precise diagnostic tools to facilitate early detection and effective management. Neurodiagnostic techniques, including advanced imaging modalities and electrophysiological studies, play a pivotal role in providing insights into the structure and function of the nervous system. Additionally, growing awareness of the importance of early diagnosis, coupled with continuous technological advancements in neurodiagnostics, propels the market forward.

Restraint:

High cost of neurodiagnostic devices

The high cost of neurodiagnostic devices stands as a significant restraint in the neurodiagnostics market. The sophisticated technologies utilized in neurodiagnostics, including advanced imaging equipment and monitoring devices, are costly. This elevated cost poses a barrier to the widespread adoption of neurodiagnostic tools, particularly for smaller healthcare facilities or those with budget constraints. Moreover, this financial burden can limit accessibility to cutting-edge neurodiagnostic technologies, hindering the potential for comprehensive neurological assessments and impeding the overall growth of the neurodiagnostics market.

Opportunity:

Technological advancements in neurodiagnostic devices

Continuous innovation, such as the development of high-resolution imaging techniques, wearable devices for remote monitoring, and artificial intelligence applications for data analysis, enhances diagnostic precision and patient care. These advancements offer healthcare professionals more comprehensive insights into neurological conditions. As neurodiagnostic technologies evolve, there is a growing potential for improved diagnostic accuracy, streamlined workflows, and enhanced patient outcomes, driving further adoption and expansion in the market.

Threat:

Lack of awareness among healthcare professionals

Despite the continuous advancements in neurodiagnostic technologies, a notable gap in understanding and awareness may exist among healthcare practitioners. This knowledge deficit can lead to the delayed or underutilized adoption of innovative neurodiagnostic procedures and tools. Additionally, inadequate awareness may hinder the timely diagnosis and management of neurological disorders, impacting patient outcomes.

COVID-19 Impact:

The COVID-19 pandemic has significantly impacted the neurodiagnostic market. Lockdowns, restrictions on elective procedures, and reallocation of healthcare resources have led to a decline in routine neurodiagnostic testing. Additionally, patient reluctance to visit healthcare facilities due to infection concerns has further hindered the market. However, the pandemic has accelerated the adoption of telehealth and remote monitoring solutions, offering opportunities for the neurodiagnostic market.

The Diagnostic & Imaging Systems segment is expected to be the largest during the forecast period

The diagnostic and imaging systems segment is poised for dominance in the neurodiagnostics market during the forecast period due to technological advancements and the growing demand for precise and non-invasive diagnostic tools. Advanced imaging technologies, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), contribute to accurate neurodiagnosis. Additionally, the increasing incidence of neurological disorders emphasizes the significance of diagnostic and imaging systems on the market.

The headache disorders segment is expected to have the highest CAGR during the forecast period

During the forecast period, the headache disorders segment is anticipated to experience substantial growth in the neurodiagnostics market. Factors such as the increasing prevalence of headaches, including migraines, growing awareness, and advancements in diagnostic technologies specific to headache disorders are contributing to this expansion. As healthcare providers prioritize accurate diagnosis and personalized treatment plans for individuals suffering from headaches, the demand for neurodiagnostic tools and procedures tailored to this segment is expected to rise, driving the overall growth of the market.

Region with largest share:

North America is poised to maintain its market dominance in the neurodiagnostic sector during the forecast period. The region benefits from a well-established healthcare infrastructure, technological advancements, and significant investments in research and development. Additionally, the increasing prevalence of neurological disorders, a growing aging population, and higher awareness levels contribute to the sustained demand for neurodiagnostic services. The presence of major industry players and a favorable regulatory environment further solidify North America's position in the neurodiagnostic market.

Region with highest CAGR:

The Asia Pacific region is positioned for substantial growth in the neurodiagnostic market. Factors such as a burgeoning population, rising healthcare awareness, and increasing incidences of neurological disorders drive the demand for advanced diagnostic technologies. Governments in the region are investing in healthcare infrastructure, fostering research and development, and promoting technological adoption. With a growing emphasis on healthcare quality and accessibility, coupled with a rising aging population, the Asia Pacific neurodiagnostic market is expected to witness significant expansion.

Key players in the market:

Some of the key players in Neurodiagnostics Market include GE Healthcare, Advanced Brain Monitoring, Inc, Bio-Rad Laboratories, Canon, Inc., F. Hoffmann-La Roche AG, Fujifilm Corporation, GE Healthcare, Hitachi Ltd., Hoffman-La Roche AG, Koninklijke Philips N.V., Lifelines Neuro Company LLC, Mitsar Co. Ltd., Natus Medical Incorporated, Nihon Kohden Corporation, QIAGEN N.V., Siemens Healthineers and Thermo Fisher Scientific Inc.

Key Developments:

In November 2023, QIAGEN announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research.

In October 2023, QIAGEN and Myriad Genetics announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The partnership aims to deliver innovative services and products to pharmaceutical companies, enabling the development and commercialization of proprietary cancer tests for the U.S. clinical market, and providing distributable companion diagnostic test kits for the global market.

In May 2022, Bruker launched an innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its preclinical magnetic resonance imaging (MRI) portfolio. The new range of Maxwell 7 Tesla and 9.4 Tesla magnets eliminates the need for liquid helium or nitrogen refills while offering high-field sensitivity and resolution for advanced preclinical MRI and PET/MR research.

Products Covered:

  • Diagnostic & Imaging Systems
  • Clinical Diagnostic Instruments
  • Reagents & Consumables
  • Other Products

Conditions Covered:

  • Neurodegenerative Diseases
  • Epilepsy
  • Headache Disorders
  • Sleep Disorders
  • Other Conditions

End Users Covered:

  • Hospitals
  • Ambulatory Care Centers
  • Diagnostic Laboratories & Imaging Centers
  • Neurology Centers
  • Research Laboratories & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurodiagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostic & Imaging Systems
    • 5.2.1 Angiography Systems
    • 5.2.2 Computed Tomography (CT) Scanners
    • 5.2.3 Electroencephalogram (EEG) Systems
    • 5.2.4 Electromyography (EMG) Devices
    • 5.2.5 Magnetic Resonance Imaging (MRI) Systems
    • 5.2.6 Magnetoencephalography (MEG) Devices
    • 5.2.7 Positron emission tomography (PET) Scanners
    • 5.2.8 Ultrasound Imaging Systems
    • 5.2.9 Other Diagnostic & Imaging Systems
  • 5.3 Clinical Diagnostic Instruments
    • 5.3.1 Next-generation Sequencing Instruments
    • 5.3.2 Polymerase Chain Reaction (PCR) Instruments
    • 5.3.3 Sanger Sequencers
    • 5.3.4 Other Clinical Diagnostic Instruments
  • 5.4 Reagents & Consumables
    • 5.4.1 Antibodies
    • 5.4.2 Buffers
    • 5.4.3 Enzymes, Proteins, & Peptides
    • 5.4.4 Media & Sera
    • 5.4.5 Probes
    • 5.4.6 Solvents
    • 5.4.7 Other Reagents & Consumables
  • 5.5 Other Products

6 Global Neurodiagnostics Market, By Condition

  • 6.1 Introduction
  • 6.2 Neurodegenerative Diseases
  • 6.3 Epilepsy
  • 6.4 Headache Disorders
  • 6.5 Sleep Disorders
  • 6.6 Other Conditions

7 Global Neurodiagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Ambulatory Care Centers
  • 7.4 Diagnostic Laboratories & Imaging Centers
  • 7.5 Neurology Centers
  • 7.6 Research Laboratories & Academic Institutes
  • 7.7 Other End Users

8 Global Neurodiagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 GE Healthcare
  • 10.2 Advanced Brain Monitoring, Inc
  • 10.3 Bio-Rad Laboratories
  • 10.4 Canon, Inc.
  • 10.5 F. Hoffmann-La Roche AG
  • 10.6 Fujifilm Corporation
  • 10.7 GE Healthcare
  • 10.8 Hitachi Ltd.
  • 10.9 Hoffman-La Roche AG
  • 10.10 Koninklijke Philips N.V.
  • 10.11 Lifelines Neuro Company LLC
  • 10.12 Mitsar Co. Ltd.
  • 10.13 Natus Medical Incorporated
  • 10.14 Nihon Kohden Corporation
  • 10.15 QIAGEN N.V.
  • 10.16 Siemens Healthineers
  • 10.17 Thermo Fisher Scientific Inc.

List of Tables

  • Table 1 Global Neurodiagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neurodiagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Neurodiagnostics Market Outlook, By Diagnostic & Imaging Systems (2021-2030) ($MN)
  • Table 4 Global Neurodiagnostics Market Outlook, By Angiography Systems (2021-2030) ($MN)
  • Table 5 Global Neurodiagnostics Market Outlook, By Computed Tomography (CT) Scanners (2021-2030) ($MN)
  • Table 6 Global Neurodiagnostics Market Outlook, By Electroencephalogram (EEG) Systems (2021-2030) ($MN)
  • Table 7 Global Neurodiagnostics Market Outlook, By Electromyography (EMG) Devices (2021-2030) ($MN)
  • Table 8 Global Neurodiagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) Systems (2021-2030) ($MN)
  • Table 9 Global Neurodiagnostics Market Outlook, By Magnetoencephalography (MEG) Devices (2021-2030) ($MN)
  • Table 10 Global Neurodiagnostics Market Outlook, By Positron emission tomography (PET) Scanners (2021-2030) ($MN)
  • Table 11 Global Neurodiagnostics Market Outlook, By Ultrasound Imaging Systems (2021-2030) ($MN)
  • Table 12 Global Neurodiagnostics Market Outlook, By Other Diagnostic & Imaging Systems (2021-2030) ($MN)
  • Table 13 Global Neurodiagnostics Market Outlook, By Clinical Diagnostic Instruments (2021-2030) ($MN)
  • Table 14 Global Neurodiagnostics Market Outlook, By Next-generation Sequencing Instruments (2021-2030) ($MN)
  • Table 15 Global Neurodiagnostics Market Outlook, By Polymerase Chain Reaction (PCR) Instruments (2021-2030) ($MN)
  • Table 16 Global Neurodiagnostics Market Outlook, By Sanger Sequencers (2021-2030) ($MN)
  • Table 17 Global Neurodiagnostics Market Outlook, By Other Clinical Diagnostic Instruments (2021-2030) ($MN)
  • Table 18 Global Neurodiagnostics Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
  • Table 19 Global Neurodiagnostics Market Outlook, By Antibodies (2021-2030) ($MN)
  • Table 20 Global Neurodiagnostics Market Outlook, By Buffers (2021-2030) ($MN)
  • Table 21 Global Neurodiagnostics Market Outlook, By Enzymes, Proteins, & Peptides (2021-2030) ($MN)
  • Table 22 Global Neurodiagnostics Market Outlook, By Media & Sera (2021-2030) ($MN)
  • Table 23 Global Neurodiagnostics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 24 Global Neurodiagnostics Market Outlook, By Solvents (2021-2030) ($MN)
  • Table 25 Global Neurodiagnostics Market Outlook, By Other Reagents & Consumables (2021-2030) ($MN)
  • Table 26 Global Neurodiagnostics Market Outlook, By Condition (2021-2030) ($MN)
  • Table 27 Global Neurodiagnostics Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 28 Global Neurodiagnostics Market Outlook, By Epilepsy (2021-2030) ($MN)
  • Table 29 Global Neurodiagnostics Market Outlook, By Headache Disorders (2021-2030) ($MN)
  • Table 30 Global Neurodiagnostics Market Outlook, By Sleep Disorders (2021-2030) ($MN)
  • Table 31 Global Neurodiagnostics Market Outlook, By Other Conditions (2021-2030) ($MN)
  • Table 32 Global Neurodiagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Neurodiagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 34 Global Neurodiagnostics Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 35 Global Neurodiagnostics Market Outlook, By Diagnostic Laboratories & Imaging Centers (2021-2030) ($MN)
  • Table 36 Global Neurodiagnostics Market Outlook, By Neurology Centers (2021-2030) ($MN)
  • Table 37 Global Neurodiagnostics Market Outlook, By Research Laboratories & Academic Institutes (2021-2030) ($MN)
  • Table 38 Global Neurodiagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.